Preliminary biological evaluation of 123I-labelled anti-CD30-LDM in CD30-positive lymphomas murine models

References

• Vaklavas C, Forero-Torres A. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Ther Adv Hematol. 2012;3(4):209–225.
   PubMedGoogle Scholar
• Shinoda K, Sun X, Oyamada A, et al. CD30 ligand is a new therapeutic target for central nervous system autoimmunity. J Autoimmun. 2015;57:14–23.
   PubMed Web of Science ®Google Scholar
• Blatt K, Cerny-Reiterer S, Schwaab J, et al. Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis. Blood. 2015;126(26):2832–2841.
   PubMed Web of Science ®Google Scholar
• Muta H, Podack ER. CD30: from basic research to cancer therapy. Immunol Res. 2013;57(1–3):151–158.
   PubMed Web of Science ®Google Scholar
• Hombach AA, Gorgens A, Chmielewski M, et al. Superior Therapeutic Index in lymphoma therapy: CD30(+) CD34(+) hematopoietic stem cells resist a chimeric antigen receptor T-cell attack. Mol Ther. 2016;24(8):1423–1434.
   PubMed Web of Science ®Google Scholar
• Jagadeesh D, Smith MR. Antibody Drug Conjugates (ADCs): changing the treatment landscape of lymphoma. Curr Treat Options Oncol. 2016;17(10):55.
   PubMed Web of Science ®Google Scholar
• Chen R, Gopal AK, Smith SE, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128(12):1562–1566.
   PubMed Web of Science ®Google Scholar
• Horwitz S, O'Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229–240.
   PubMed Web of Science ®Google Scholar
• Chen R, Hou J, Newman E, et al. CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol Cancer Ther. 2015;14(6):1376–1384.
   PubMed Web of Science ®Google Scholar
• Shao RG, Zhen YS. Enediyne anticancer antibiotic lidamycin: chemistry, biology and pharmacology. ACAMC. 2008;8(2):123–131.
   Web of Science ®Google Scholar
• Guo XF, Zhu XF, Shang Y, et al. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity. Clin Cancer Res. 2010;16(7):2085–2094.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Fukuda-Ishisaka S, Hirama M, et al. Solution structures of C-1027 apoprotein and its complex with the aromatized chromophore. J Mol Biol. 2001;309(1):267–283.
   PubMed Web of Science ®Google Scholar
• Wang R, Li L, Zhang S, et al. A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30(+) lymphomas. Mol Oncol. 2018;12(3):339–355.
   PubMed Web of Science ®Google Scholar
• Beerman TA, Gawron LS, Shen B, et al. The radiomimetic enediyne, 20'-deschloro-C-1027 induces inter-strand DNA crosslinks in hypoxic cells and overcomes cytotoxic radioresistance. DNA Repair (Amst). 2014;21:165–170.
   PubMed Web of Science ®Google Scholar
• Beerman TA, Gawron LS, Shin S, et al. C-1027, a radiomimetic enediyne anticancer drug, preferentially targets hypoxic cells. Cancer Res. 2009;69(2):593–598.
   PubMed Web of Science ®Google Scholar
• Wang R, Li L, Duan A, et al. Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma. Cancer Lett. 2019;448:84–93.
   PubMed Web of Science ®Google Scholar
• Han TH, Zhao B. Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates. Drug Metab Dispos. 2014;42(11):1914–1920.
   PubMedGoogle Scholar
• Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555–566.
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Lue JK, Sawas A, et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial. Lancet Oncol. 2018;19(2):257–266.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Chihara D, Horowitz S, et al. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol. 2016;27(7):1317–1323.
   PubMed Web of Science ®Google Scholar
• Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130(25):2709–2717.
   PubMed Web of Science ®Google Scholar
• Poston JN, Fromm JR, Rasmussen HA, et al. A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks. Br J Haematol. 2018;186(1):159–162.
   PubMed Web of Science ®Google Scholar
• Bilardi RA, Kimura KI, Phillips DR, et al. Processing of anthracycline-DNA adducts via DNA replication and interstrand crosslink repair pathways. Biochem Pharmacol. 2012;83(9):1241–1250.
   PubMed Web of Science ®Google Scholar
• Rylova SN, Del Pozzo L, Klingeberg C, et al. Immuno-PET imaging of CD30-positive lymphoma using 89Zr-desferrioxamine-labeled CD30-specific AC-10 antibody. J Nucl Med. 2016;57(1):96–102.
   PubMed Web of Science ®Google Scholar
• Schnell R, Dietlein M, Staak JO, et al. Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. JCO. 2005;23(21):4669–4678.
   PubMed Web of Science ®Google Scholar
• Zhang M, Yao Z, Patel H, et al. Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1. Proc Natl Acad Sci USA. 2007;104(20):8444–8448.
   PubMed Web of Science ®Google Scholar
• Dietlein M, Borner SM, Fischer T, et al. Development of anti-CD30 radioimmunoconstructs (RICs) for treatment of Hodgkin's lymphoma. Studies with cell lines and animal studies. Nuklearmedizin. 2010;49(3):97–105.
   PubMedGoogle Scholar
• Kang L, Jiang D, Ehlerding EB, et al. Noninvasive trafficking of brentuximab vedotin and PET imaging of CD30 in lung cancer murine models. Mol Pharm. 2018;15(4):1627–1634.
   PubMed Web of Science ®Google Scholar
• Plattel WJ, Alsada ZN, van Imhoff GW, et al. Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin-1, sCD163 and sCD30 with TARC. Br J Haematol. 2016;175(5):868–875.
   PubMed Web of Science ®Google Scholar
• Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol. 1998;10(6):457–470.
   PubMed Web of Science ®Google Scholar
• Purdue MP, Lan Q, Kemp TJ, et al. Elevated serum sCD23 and sCD30 up to two decades prior to diagnosis associated with increased risk of non-Hodgkin lymphoma. Leukemia. 2015;29(6):1429–1431.
   PubMed Web of Science ®Google Scholar